Tenofovir (cas 107021-12-5) Alafenamide and Tenofovir (cas 107021-12-5) Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2

Add time:08/08/2019    Source:sciencedirect.com

Tenofovir (cas 107021-12-5)-associated renal toxicity is influenced by several factors, including plasma exposure and genetic variants in transporter-encoding genes. Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher plasma tenofovir concentrations, compared to CC group.In literature, substrate studies are lacking; for this reason, our aim was to understand if tenofovir and tenofovir-alafenamide are CNT2 substrates.We performed an in vitro study using CNT2 expressing MDCKII cells.We observed that tenofovir and tenofovir-alafenamide are not substrates of CNT2.Tenofovir-alafenamide influx pathway remains to be clarified.

We also recommend Trading Suppliers and Manufacturers of Tenofovir (cas 107021-12-5). Pls Click Website Link as below: cas 107021-12-5 suppliers

Prev:Simultaneous determination of Tenofovir (cas 107021-12-5) alafenamide and Tenofovir (cas 107021-12-5) in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic
Next:Development and validation of an LC–MS/MS assay for Tenofovir (cas 107021-12-5) and Tenofovir (cas 107021-12-5) alafenamide in human plasma and cerebrospinal fluid)